Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Urology
Volume 2017, Article ID 7083451, 3 pages
https://doi.org/10.1155/2017/7083451
Case Report

Hyper IgE Syndrome and Renal Cell Carcinoma

Department of Urology, New York Medical College, Valhalla, NY, USA

Correspondence should be addressed to Neel H. Patel; moc.liamg@letaphleen

Received 3 March 2017; Accepted 26 April 2017; Published 18 May 2017

Academic Editor: Sandhya Srinivas

Copyright © 2017 Neel H. Patel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. F. Freeman and S. M. Holland, “The hyper-IgE syndromes,” Immunology and Allergy Clinics of North America, vol. 28, no. 2, pp. 277–291, 2008. View at Publisher · View at Google Scholar
  2. A. F. Freeman and S. M. Holland, “Clinical manifestations, etiology, and pathogenesis of the hyper-IgE syndromes,” Pediatric Research, vol. 65, no. 5, pp. 32R–37R, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. I. Oztop, B. Demirkan, O. Tarhan et al., “The development of pulmonary adenocarcinoma in a patient with Job's syndrome, a rare immunodeficiency condition,” Tumori, vol. 90, no. 1, pp. 132–135, 2004. View at Google Scholar · View at Scopus
  4. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2017,” CA: A Cancer Journal for Clinicians, vol. 67, no. 1, pp. 7–30, 2017. View at Publisher · View at Google Scholar
  5. K. Salavoura, A. Kolialexi, G. Tsangaris, and A. Mavrou, “Development of cancer in patients with primary immunodeficiencies,” Anticancer Research, vol. 28, no. 2B, pp. 1263–1269, 2008. View at Google Scholar · View at Scopus
  6. B. Escudier, “Emerging immunotherapies for renal cell carcinoma,” Annals of Oncology, vol. 23, no. Supplement 8, pp. viii35–viii40, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Wierecky, M. R. Müller, S. Wirths et al., “Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients,” Cancer Research, vol. 66, no. 11, pp. 5910–5918, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Noessner, D. Brech, A. N. Mendler, I. Masouris, R. Schlenker, and P. U. Prinz, “Intratumoral alterations of dendritic-cell differentiation and CD8(+) T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma,” OncoImmunology, vol. 1, no. 8, pp. 1451–1453, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Tatsugami and M. Itsumi, “Immunotherapy for renal cell carcinoma,” Clinical and Developmental Immunology, vol. 2010, Article ID 284581, 8 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Akira, “Roles of STAT3 defined by tissue-specific gene targeting,” Oncogene, vol. 19, no. 21, pp. 2607–2611, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Minegishi and M. Saito, “Molecular mechanisms of the immunological abnormalities in hyper-IgE syndrome,” Annals of the New York Academy of Sciences, vol. 1246, no. 1, pp. 34–40, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Grimbacher, S. M. Holland, J. I. Gallin et al., “Hyper-IgE syndrome with recurrent infections—an autosomal dominant multisystem disorder,” The New England Journal of Medicine, vol. 340, no. 9, pp. 692–702, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Li, C. Yang, Z. Zhao et al., “Skewed T-helper (Th)1/2- and Th17/T regulatorycell balances in patients with renal cell carcinoma,” Molecular Medicine Reports, vol. 11, no. 2, pp. 947–953, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Sell, P. J. Barth, R. Moll et al., “Localization of FOXP3-positive cells in renal cell carcinoma,” Tumor Biology, vol. 33, no. 2, pp. 507–513, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Beerlage, J. Greb, D. Kretschmer et al., “Hypoxia-inducible factor 1-regulated lysyl oxidase is involved in Staphylococcus aureus abscess formation,” Infection and Immunity, vol. 81, no. 7, pp. 2562–2573, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. H. E. Barker, T. R. Cox, and J. T. Erler, “The rationale for targeting the LOX family in cancer,” Nature Reviews Cancer, vol. 12, no. 8, pp. 540–552, 2012. View at Publisher · View at Google Scholar · View at Scopus